165 related articles for article (PubMed ID: 37451320)
1. Human toll-like receptor 8 (TLR8) in NK cells: Implication for cancer immunotherapy.
Veneziani I; Alicata C; Moretta L; Maggi E
Immunol Lett; 2023 Sep; 261():13-16. PubMed ID: 37451320
[TBL] [Abstract][Full Text] [Related]
2. Toll-like receptor 8 agonists improve NK-cell function primarily targeting CD56
Veneziani I; Alicata C; Pelosi A; Landolina N; Ricci B; D'Oria V; Fagotti A; Scambia G; Moretta L; Maggi E
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35091452
[TBL] [Abstract][Full Text] [Related]
3. The Latest Approach of Immunotherapy with Endosomal TLR Agonists Improving NK Cell Function: An Overview.
Veneziani I; Alicata C; Moretta L; Maggi E
Biomedicines; 2022 Dec; 11(1):. PubMed ID: 36672572
[TBL] [Abstract][Full Text] [Related]
4. Accessory-cell-mediated activation of porcine NK cells by toll-like receptor 7 (TLR7) and TLR8 agonists.
Toka FN; Nfon CK; Dawson H; Golde WT
Clin Vaccine Immunol; 2009 Jun; 16(6):866-78. PubMed ID: 19369481
[TBL] [Abstract][Full Text] [Related]
5. TLR8 combined withTLR3 or TLR4 agonists enhances DC-NK driven effector Tc1 cells.
Nouri-Shirazi M; Tamjidi S; Nourishirazi E; Guinet E
Immunol Lett; 2018 Jan; 193():58-66. PubMed ID: 29103998
[TBL] [Abstract][Full Text] [Related]
6. Toll-like receptor-targeted particles: A paradigm to manipulate the tumor microenvironment for cancer immunotherapy.
Tran TH; Tran TTP; Truong DH; Nguyen HT; Pham TT; Yong CS; Kim JO
Acta Biomater; 2019 Aug; 94():82-96. PubMed ID: 31129358
[TBL] [Abstract][Full Text] [Related]
7. Cancer immunotherapeutic potential of novel small molecule TLR7 and TLR8 agonists.
Hamm S; Rath S; Michel S; Baumgartner R
J Immunotoxicol; 2009 Dec; 6(4):257-65. PubMed ID: 19848448
[TBL] [Abstract][Full Text] [Related]
8. Combination of TLR8 and TLR4 agonists reduces the degrading effects of nicotine on DC-NK mediated effector T cell generation.
Nouri-Shirazi M; Tamjidi S; Nourishirazi E; Guinet E
Int Immunopharmacol; 2018 Aug; 61():54-63. PubMed ID: 29803914
[TBL] [Abstract][Full Text] [Related]
9. TLR8 stimulation enhances cetuximab-mediated natural killer cell lysis of head and neck cancer cells and dendritic cell cross-priming of EGFR-specific CD8+ T cells.
Stephenson RM; Lim CM; Matthews M; Dietsch G; Hershberg R; Ferris RL
Cancer Immunol Immunother; 2013 Aug; 62(8):1347-57. PubMed ID: 23685782
[TBL] [Abstract][Full Text] [Related]
10. TLR7/8 Agonist-Loaded Nanoparticles Augment NK Cell-Mediated Antibody-Based Cancer Immunotherapy.
Kim H; Khanna V; Kucaba TA; Zhang W; Sehgal D; Ferguson DM; Griffith TS; Panyam J
Mol Pharm; 2020 Jun; 17(6):2109-2124. PubMed ID: 32383885
[TBL] [Abstract][Full Text] [Related]
11. TLR7/8-mediated activation of human NK cells results in accessory cell-dependent IFN-gamma production.
Hart OM; Athie-Morales V; O'Connor GM; Gardiner CM
J Immunol; 2005 Aug; 175(3):1636-42. PubMed ID: 16034103
[TBL] [Abstract][Full Text] [Related]
12. TLR7/8 agonists promote NK-DC cross-talk to enhance NK cell anti-tumor effects in hepatocellular carcinoma.
Zhou Z; Yu X; Zhang J; Tian Z; Zhang C
Cancer Lett; 2015 Dec; 369(2):298-306. PubMed ID: 26433159
[TBL] [Abstract][Full Text] [Related]
13. Synergistical toll-like receptors activated dendritic cells induce antitumor effects against carcinoembryonic antigen-expressing colon cancer.
Hong X; Dong T; Hu J; Yi T; Li W; Zhang Z; Lin S; Niu W
Int J Colorectal Dis; 2013 Jan; 28(1):25-33. PubMed ID: 22777000
[TBL] [Abstract][Full Text] [Related]
14. Toll-Like Receptors in Natural Killer Cells and Their Application for Immunotherapy.
Noh JY; Yoon SR; Kim TD; Choi I; Jung H
J Immunol Res; 2020; 2020():2045860. PubMed ID: 32377528
[TBL] [Abstract][Full Text] [Related]
15. Toll-like receptor expression and function in human dendritic cell subsets: implications for dendritic cell-based anti-cancer immunotherapy.
Schreibelt G; Tel J; Sliepen KH; Benitez-Ribas D; Figdor CG; Adema GJ; de Vries IJ
Cancer Immunol Immunother; 2010 Oct; 59(10):1573-82. PubMed ID: 20204387
[TBL] [Abstract][Full Text] [Related]
16. Src kinases are required for a balanced production of IL-12/IL-23 in human dendritic cells activated by Toll-like receptor agonists.
Kuka M; Baronio R; Valentini S; Monaci E; Muzzi A; Aprea S; De Gregorio E; D'Oro U
PLoS One; 2010 Jul; 5(7):e11491. PubMed ID: 20634889
[TBL] [Abstract][Full Text] [Related]
17. In vivo cancer vaccination: Which dendritic cells to target and how?
Chiang CL; Kandalaft LE
Cancer Treat Rev; 2018 Dec; 71():88-101. PubMed ID: 30390423
[TBL] [Abstract][Full Text] [Related]
18. Distinct indirect pathways govern human NK-cell activation by TLR-7 and TLR-8 agonists.
Gorski KS; Waller EL; Bjornton-Severson J; Hanten JA; Riter CL; Kieper WC; Gorden KB; Miller JS; Vasilakos JP; Tomai MA; Alkan SS
Int Immunol; 2006 Jul; 18(7):1115-26. PubMed ID: 16728430
[TBL] [Abstract][Full Text] [Related]
19. Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies.
Mullins SR; Vasilakos JP; Deschler K; Grigsby I; Gillis P; John J; Elder MJ; Swales J; Timosenko E; Cooper Z; Dovedi SJ; Leishman AJ; Luheshi N; Elvecrog J; Tilahun A; Goodwin R; Herbst R; Tomai MA; Wilkinson RW
J Immunother Cancer; 2019 Sep; 7(1):244. PubMed ID: 31511088
[TBL] [Abstract][Full Text] [Related]
20. Enhancement of antitumor effect using dendritic cells activated with natural killer cells in the presence of Toll-like receptor agonist.
Pham TN; Hong CY; Min JJ; Rhee JH; Nguyen TA; Park BC; Yang DH; Park YK; Kim HR; Chung IJ; Kim HJ; Lee JJ
Exp Mol Med; 2010 Jun; 42(6):407-19. PubMed ID: 20386085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
